Next Article in Journal
Protection and Safety Evaluation of Live Constructions Derived from the Pgm− and pPCP1− Yersinia pestis Strain
Previous Article in Journal
Clinical Challenges in a 49-Year-Old Patient with Severe Tick-Borne Myeloradiculitis Despite Complete Active Vaccination
Previous Article in Special Issue
Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 8
Issue 1
10.3390/vaccines8010094
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Vaccines 2019, 7(3), 72.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72

by
Gustavo Cabral-Miranda
1,2,*,
Stephanie M. Lim
3,
Mona O. Mohsen
1,2,
Ilya V. Pobelov
4,
Elisa S. Roesti
2,
Matthew D. Heath
5,
Murray A. Skinner
5,
Matthias F. Kramer
5,
Byron E. E. Martina
3,6 and
Martin F. Bachmann
1,2,*
1
The Jenner Institute, Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), University of Oxford, Oxford OX1 2JD, UK
2
Immunology, RIA, Inselspital, University of Bern, 3010 Bern, Switzerland
3
Artemis Bio-Support, Molengraaffsingel, 2629 Delft, The Netherlands
4
Department of Chemistry and Biochemistry, University of Bern, 3010 Bern, Switzerland
5
Bencard Adjuvant Systems, Worthing BN14 8SA, UK
6
Department of Viroscience, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
*
Authors to whom correspondence should be addressed.
Vaccines 2020, 8(1), 94; https://doi.org/10.3390/vaccines8010094
Submission received: 13 February 2020 / Accepted: 19 February 2020 / Published: 20 February 2020
(This article belongs to the Special Issue Arbovirus Vaccines That Circulate within the Same Ecological Niche: Zika, Dengue & Chikungunya)
Browse Figures
Review Reports Versions Notes
The authors wish to make the following correction to their paper [1].
The same image was mistakenly selected for Figure 2 and Figure 3. The image became replaced as you see in Figure 3 below.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Reference

  1. Cabral-Miranda, G.; Lim, S.M.; Mohsen, M.O.; Pobelov, I.V.; Roesti, E.S.; Heath, M.D.; Skinner, M.A.; Kramer, M.F.; Martina, B.E.E.; Bachmann, M.F. Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72. [Google Scholar] [CrossRef] [Green Version]
Vaccines 08 00094 g002 550
Figure 2. CuMVtt-EDIII formulated in DOPS indices highest total IgG responses. The figure shows IgGs level of three different groups of mice vaccinated with EDIII alone formulated in phosphate-buffered saline (PBS), with vaccine formulated by coupling EDIII to VLP (CuMVtt-EDIII) or formulating CuMVtt-EDIII plus DOPS adjuvant. The assessment was done with sera collected three weeks after each vaccination. The results were analyzed using GraphPad Prism software applied to assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in the negative control group (vaccinated with only PBS) were subtracted from the titers of the other experimental groups. Note: * p < 0.01, ** p < 0.001, *** p < 0.0001.
Figure 2. CuMVtt-EDIII formulated in DOPS indices highest total IgG responses. The figure shows IgGs level of three different groups of mice vaccinated with EDIII alone formulated in phosphate-buffered saline (PBS), with vaccine formulated by coupling EDIII to VLP (CuMVtt-EDIII) or formulating CuMVtt-EDIII plus DOPS adjuvant. The assessment was done with sera collected three weeks after each vaccination. The results were analyzed using GraphPad Prism software applied to assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in the negative control group (vaccinated with only PBS) were subtracted from the titers of the other experimental groups. Note: * p < 0.01, ** p < 0.001, *** p < 0.0001.
Vaccines 08 00094 g002
Vaccines 08 00094 g003 550
Figure 3. Subclasses of IgG. The figure shows the specific subclasses of IgG induced by each vaccine from samples collected three weeks after the third vaccination (Day 63). The group of mice vaccinated with only EDIII predominantly produced IgG1 while EDIII coupled to VLP (CuMVtt-EDIII) also induced IgG2a and IgG2b. When DOPS adjuvant was ad-mixed, this skewing towards IgG2a and b was even more pronounced. The results were analyzed using GraphPad Prism software applied to assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in the negative control group were subtracted from the titers of the other experimental groups. Note: ** p < 0.001, *** p < 0.0001.
Figure 3. Subclasses of IgG. The figure shows the specific subclasses of IgG induced by each vaccine from samples collected three weeks after the third vaccination (Day 63). The group of mice vaccinated with only EDIII predominantly produced IgG1 while EDIII coupled to VLP (CuMVtt-EDIII) also induced IgG2a and IgG2b. When DOPS adjuvant was ad-mixed, this skewing towards IgG2a and b was even more pronounced. The results were analyzed using GraphPad Prism software applied to assess the means of three groups by one-way analysis of variance (ANOVA). The values observed in the negative control group were subtracted from the titers of the other experimental groups. Note: ** p < 0.001, *** p < 0.0001.
Vaccines 08 00094 g003

Share and Cite

MDPI and ACS Style

Cabral-Miranda, G.; Lim, S.M.; Mohsen, M.O.; Pobelov, I.V.; Roesti, E.S.; Heath, M.D.; Skinner, M.A.; Kramer, M.F.; Martina, B.E.E.; Bachmann, M.F. Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72. Vaccines 2020, 8, 94. https://doi.org/10.3390/vaccines8010094

AMA Style

Cabral-Miranda G, Lim SM, Mohsen MO, Pobelov IV, Roesti ES, Heath MD, Skinner MA, Kramer MF, Martina BEE, Bachmann MF. Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72. Vaccines. 2020; 8(1):94. https://doi.org/10.3390/vaccines8010094

Chicago/Turabian Style

Cabral-Miranda, Gustavo, Stephanie M. Lim, Mona O. Mohsen, Ilya V. Pobelov, Elisa S. Roesti, Matthew D. Heath, Murray A. Skinner, Matthias F. Kramer, Byron E. E. Martina, and Martin F. Bachmann. 2020. "Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72" Vaccines 8, no. 1: 94. https://doi.org/10.3390/vaccines8010094

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop